Metolazone NDC 50742-349

NDC codes

FDA NDC Directory

Product NDC (as listed)50742-349Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50742-0349Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50742-349-01	50742034901	100 TABLET in 1 BOTTLE (50742-349-01)Marketed from Jan 24, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metolazone
Generic name (nonproprietary): metolazone
Active ingredients: Metolazone — 2.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Ingenus Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215616
Marketing start: Jan 24, 2023
Listing expires: Dec 31, 2026
Other FDA classes: Increased Diuresis (Physiologic effect)
Identifiers: Product ID 50742-349_40a518ac-5d45-4c61-e063-6294a90a6ec9SPL ID 40a518ac-5d45-4c61-e063-6294a90a6ec9SPL set ID 1e566c10-4498-4f79-8874-4cc8c4216213RxCUI 197978, 197979, 311671UNII TZ7V40X7VX
Pharmacologic class: Thiazide-like Diuretic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450742034901 followed by a unit qualifier and the quantity

Package 50742-0349-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 8, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Metolazone tablets are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for metolazone tablets in the treatment of hypertension. See pa…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215616

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215616
Product	Strength	Form · route	Labeler	Product NDC
Metolazone	Metolazone 5 mg/1	TabletOral	Major Pharmaceuticals	0904-7521
Metolazone	Metolazone 2.5 mg/1	TabletOral	Major Pharmaceuticals	0904-7520
Metolazone	Metolazone 10 mg/1	TabletOral	Ingenus Pharmaceuticals LLC	50742-351
Metolazone	Metolazone 5 mg/1	TabletOral	Ingenus Pharmaceuticals LLC	50742-350